The MHRA is consulting with UK stakeholders to gather feedback and comments on ICH E20, a new international guideline.
Similar Posts
MHRA updates guidance for GLP-1 prescribers and patients
Updated product information for healthcare professionals and patients regarding the small risk of severe acute pancreatitis in patients taking GLP-1s.
Cancel a medicine’s marketing authorisation or other licence
Cancel a marketing authorisation, traditional herbal registration or parallel import product licence or withdraw a pending submission.
Field Safety Notices: 23-27 February 2026
List of Field Safety Notices from 23-27 February 2026.
Medicines regulator approves up to 7.2mg dose of semaglutide (Wegovy) for patients with obesity only
The Medicines and Healthcare products Regulatory Agency (MHRA) approved a maximum dose of up to 7.2mg per week of semaglutide (Wegovy) on 6 January 2026.
Breast implant associated anaplastic large cell lymphoma (BIA-ALCL)
Information for patients, public and healthcare professionals.
If you take a GLP-1 medicine and have been hospitalised by acute pancreatitis, the Yellow Card Biobank wants to hear from you
GLP-1 medicines are licensed for Type 2 diabetes and weight management, and include the branded products Ozempic, Mounjaro and Wegovy